You Su Jeong, Kang Hoon-Chul, Kim Heung Dong, Lee Hyun Sug, Ko Tae-Sung
Department of Pediatrics, Epilepsy Center, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, South Korea.
Brain Dev. 2008 Apr;30(4):287-90. doi: 10.1016/j.braindev.2007.09.004. Epub 2007 Oct 23.
To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS).
We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers.
Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up.
Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.
评估唑尼沙胺（ZNS）作为 Lennox-Gastaut 综合征（LGS）患儿长期辅助治疗的疗效和安全性。
我们在三个三级中心评估了 62 例接受 ZNS 治疗至少 12 个月的 LGS 患者的癫痫发作频率、认知结局和副作用。
在 62 例接受 ZNS 治疗的 LGS 患者中，3 例（4.8%）癫痫发作得到 100%控制；14 例（22.6%）癫痫发作频率降低 >75%至<100%；15 例（24.2%）癫痫发作频率降低 >50%至<75%；6 例（9.7%）癫痫发作频率降低 >0%至<50%，24 例（38.7%）癫痫发作无减少。癫痫发作结局与癫痫发作类型或病因无关。不良事件包括嗜睡和厌食，但均为短暂性，通过仔细随访成功处理。
我们的结果表明，ZNS 辅助治疗对小儿 LGS 患者安全有效。
Zotero 插件